载阿霉素介孔二氧化硅纳米粒的细胞毒性及细胞摄取Cytotoxicity and cellular uptake of doxorubicin-loaded mesoporous silica nanoparticles
徐爱仁,陈晶晶,马卫成,应景艳,陈武,金一
XU Ai-ren1,CHEN Jing-jing2,MA Wei-cheng1,YING Jing-yan1,CHEN Wu1,JIN Yi3(1.Department of Pharmacy
摘要(Abstract)：
目的制备载阿霉素的介孔二氧化硅纳米粒(mesoporous silica nanoparticles,MSN),对其理化性质及细胞摄取行为进行初步研究。方法通过聚合法制备MSN,透射电镜表征纳米粒的形态,动态光散射粒径测定仪测定粒子的平均粒径及分布。紫外分光光度计测定阿霉素的负载行为,MTT比色分析法研究粒子的细胞毒性,激光共聚焦显微镜观察其人乳腺癌MCF-7细胞对载药粒子的摄取。结果纳米粒分布均一,平均粒径约70 nm(PDI<0.1),载药量质量分数达到20%。MCF-7细胞对载药粒子的摄取较快,空白纳米粒具有较低的细胞毒性。结论介孔二氧化硅纳米粒具有较高的药物载药量和良好的生物相容性,能较快地被对人乳腺癌MCF-7细胞摄取,有望成为一种新型的药物化疗载体。
Objective To prepare doxorubicin-loaded mesoporous silica nanoparticles and evaluate its biocompatibility and function of delivering doxorubicin into cancer cells.Methods Mesoporous silica nanoparticles(MSN)were achieved by condensation methods.The morphology was examined by transmission electron microscope and dynamic light scattering particle size and analyzer.Doxorubicin loaded MSN was achieved by stirring.The encapsulation efficiency,drug loading rate and in vitro cumulative release rate were evaluated by UV-Vis spectrophotometry.The biocompatibility of MSN was measured with MTT assay.Confocal laser scanning microscope(CLSM)was employed to study its function of delivering doxorubicin into cancer cells.Results Nanoparticles distribution was uniform.The average particle size was about 70 nm(PDI<0.1).The encapsulation efficiency and drug loading rate was above 20%(w).MSN shows good compatibility and could easily be uptaken into MCF-7 cells.Conclusions Mesoporous silica nanoparticles with high drug encapsulation efficiency can be used as the carrier of anticancer drug doxorubicin.
关键词(KeyWords)：
阿霉素;介孔二氧化硅纳米粒;体外释放;细胞摄取
doxorubicin;mesoporous silica nanoparticle;release in vitro;cellular uptake
基金项目(Foundation): 宁波市自然科学基金资助项目(2010A610022);; 浙江省自然科学基金资助项目(Y2100348)
作者(Author):
徐爱仁,陈晶晶,马卫成,应景艳,陈武,金一
XU Ai-ren1,CHEN Jing-jing2,MA Wei-cheng1,YING Jing-yan1,CHEN Wu1,JIN Yi3(1.Department of Pharmacy
DOI: 10.14066/j.cnki.cn21-1349/r.2012.12.013
参考文献(References)：
- [1]BYRNE J D,BETANCOURT T,BRANNON-PEPPAS L.Active targeting schemes for nanoparticle systems incancer therapeutics[J].Adv Drug deliv Rev,2008,60(15):1615-1626.
- [2]SLOWING I I,VIVERO-ESCOTO J L,WU C W,et al.Mesoporous silica nanoparticles as controlled releasedrug delivery and gene transfection carriers[J].AdvDrug deliv Rev,2008,60:1278-1288.
- [3]NA K,BAE Y H.Self-assembled hydrogel nanoParticlesresponsive to tumor extracellular pH from pullulan de-rivative/sulfonamide conjugate:Characterization,aggre-gation,and adriamycin release in vitro[J].Pharm Res,2002,19(5):681-688.
- [4]BIBBY D C,TALMADGEB J E,DALALA M K,et,al.Pharmacokinetics and biodistribution of RGD-targeteddoxorubicin-loaded nanoparticles in tumor-bearing mice[J].Int J Pharm,2005,293(1/2):281-290.
- [5]LAVASANIFAR A,SAMUEL J,KWON G S.Poly(eth-ylene oxide)block-poly(Lamino acid)micelles or drugdelivery[J].Adv Drug deliv Rev,2002,54(2):169-190.